Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214

Maybe I’m a little late. But in december Nektar announced the following:

Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors.  NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate the beta and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells). That’s some very nice news and the stocprice jumped.


About the author

" A wise man can learn more from a foolish question than a fool can learn from a wise answer "